AJP - Renal Physiology, Vol 263, Issue 4 613-F622, Copyright © 1992 by American Physiological Society

ARTICLES

Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin

I. A. De Lannoy, G. Koren, J. Klein, J. Charuk and M. Silverman
Department of Medicine, University of Toronto, Ontario, Canada.

We studied the in vivo luminal and contraluminal uptake of [3H]digoxin in dog kidney using the single-pass multiple indicator dilution method. A bolus tracer of 125I-albumin (plasma reference), creatinine, or L-[14C]glucose [extracellular reference (ecf)] and [3H]digoxin (or [3H]ouabain) was injected into the left renal artery, and timed serial samples were collected from the left renal vein (basolateral uptake) and left and right ureters (luminal uptake). [3H]ouabain was excreted solely by filtration and exhibited saturable and irreversible binding at the basolateral surface. Uptake of [3H]digoxin across the basolateral membrane was large and nonsaturable. Despite urine flow-dependent reabsorption and approximately 20% protein binding, the urine recovery ratio for [3H]-digoxin/glomerular (ecf) marker was 0.97 +/- 0.04 (n = 29), indicating net digoxin secretion. After intravenous infusions of cyclosporin in Cremophor EL (0.5-3.5 microM), the urine recovery ratio decreased in a dose-dependent manner from control values of 1.13 +/- 0.06 (n = 12) to 0.62 +/- 0.03 (n = 14). There was no change in the relative renal vein recovery. Left renal artery infusion of quinidine (37.5 micrograms.min-1.kg-1) decreased the relative urine recovery of [3H]digoxin by 46% (n = 6) but had no effect on postglomerular extraction. Cyclosporin and quinidine are known inhibitors of P-glycoprotein. But digoxin did not compete with [3H]azidopine for binding in rat brush-border membranes or membranes prepared from the multidrug-resistant cell line CHRC5. The exact mechanism for renal digoxin secretion remains to be determined, but our results point to a luminal localization of this secretory system.

This article has been cited by other articles:

				S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF]

				S. Song, H. Suzuki, R. Kawai, and Y. Sugiyama Effect of PSC 833, a P-Glycoprotein Modulator, on the Disposition of Vincristine and Digoxin in Rats Drug Metab. Dispos., June 1, 1999; 27(6): 689 - 694. [Abstract] [Full Text]

				M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden Inhibition of P-Glycoprotein–Mediated Drug Transport : A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine Circulation, February 2, 1999; 99(4): 552 - 557. [Abstract] [Full Text] [PDF]

				J. H. M. Charuk, A. A. Grey, and R. A. F. Reithmeier Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1127 - F1139. [Abstract] [Full Text] [PDF]